KRAS mutations predict shorter survival in lung cancer

July 26, 2012

For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

(HealthDay) -- For patients with advanced lung adenocarcinomas, KRAS mutations predict shorter survival, according to a study published online July 18 in Cancer.

Melissa L. Johnson, M.D., from Northwestern University in Chicago, and colleagues examined the prognostic significance of KRASmutations using data from 1,036 patients (59 percent women; 33 percent never-smokers) with advanced lung adenocarcinomas with known EGFR and KRAS status, who were evaluated between 2002 and 2009.

The researchers found that the patients had a median age of 65 years, and 81 percent had a Karnofsky performance status of 80 percent or greater. EGFR mutations correlated with longer overall survival (hazard ratio, 0.60; P < 0.001) and KRAS mutations with shorter survival (hazard ratio, 1.21; P = 0.048), in multivariate analysis.

"In conclusion, we report here that the presence of a KRAS mutation is a poor prognostic factor for patients with lung adenocarcinomas," the authors write. "Because patients with KRAS mutations have a distinct clinical course that results in shorter survival, they should be evaluated separately in clinical trials. We recommend including KRAS testing in upfront mutation analyses along with testing for EGFR mutations and EML4-ALK to prospectively identify these patients in the clinic."

Related Stories

The epidermal growth factor receptor (EGFR) gene is essential for KRAS-driven pancreatic cancer development, according to study results presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, ...

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer ...

Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...

(HealthDay) -- A sensitive and specific gene-based classifier can be used to identify BRAF mutant colon cancer tumors and a subpopulation of BRAF wild-type tumors with poor prognosis, according to a study published March ...

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical ...

Recommended for you

Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children's Research ...

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

Resveratrol, a chemical found in red grapes, is more effective in smaller doses at preventing bowel cancer in mice than high doses, according to new research published today in the journal Science Translational Medicine.

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Use of gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy, which happens 70 percent ...

0 comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.